MIAMI, FL — October 29, 2025 — Leads & Copy — Veru Inc. (NASDAQ: VERU) has announced the commencement of an underwritten public offering of its common stock, or pre-funded warrants, along with accompanying Series A and Series B warrants.
The offering, subject to market conditions, has no guaranteed completion date, size, or terms.
Veru intends to use the net proceeds to fund the development of enobosarm, with a primary focus on Phase 2b PLATEAU clinical study activities, working capital, and potential development partners.
Canaccord Genuity LLC and Oppenheimer & Co. Inc. are the joint book-running managers for the offering.
The securities are offered pursuant to a shelf registration statement previously filed with the SEC. The offering is being made only by means of a prospectus supplement and accompanying prospectus.
The preliminary prospectus supplement will be available on the SEC’s website or by contacting Canaccord Genuity LLC or Oppenheimer & Co. Inc.
This announcement does not constitute an offer to sell or a solicitation to buy securities in any jurisdiction where such an offer would be unlawful.
Samuel Fisch, Executive Director, Investor Relations and Corporate Communications, Email: veruinvestor@verupharma.com
Source: Veru Inc.
